BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 132 filers reported holding BRIDGEBIO PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $181 | -99.9% | 6,900 | -5.5% | 0.00% | – |
| Q4 2021 | $121,000 | -76.3% | 7,300 | -33.0% | 0.00% | -100.0% |
| Q3 2021 | $510,000 | -38.0% | 10,900 | -19.3% | 0.00% | -33.3% |
| Q2 2021 | $822,000 | -6.6% | 13,500 | -5.6% | 0.00% | 0.0% |
| Q1 2021 | $880,000 | +56.9% | 14,300 | +81.0% | 0.00% | +50.0% |
| Q4 2020 | $561,000 | +183.3% | 7,900 | +49.1% | 0.00% | +100.0% |
| Q3 2020 | $198,000 | +26.9% | 5,300 | +10.4% | 0.00% | 0.0% |
| Q2 2020 | $156,000 | -24.3% | 4,800 | -18.6% | 0.00% | 0.0% |
| Q4 2019 | $206,000 | -18.3% | 5,900 | -50.0% | 0.00% | 0.0% |
| Q3 2019 | $252,000 | – | 11,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |